A Phase 1 interventional study of SHR-2173 Injection/SHR-2173 placebo in Immunology, sponsored by Atridia Pty Ltd.. Active, not recruiting at 1 site in Australia. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-29.
Sponsored by Atridia Pty Ltd. · Phase 1, Interventional, and Treatment
The purpose of this study is to assess safety, PK, Pharmacodynamic and immunogenicity profile of a single dose of SHR-2173 in healthy participants
Atridia Pty Ltd. is the lead sponsor of 34 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Main inclusion criteria
Main exclusion Criteria
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Single dose of SHR-2173/ given subcutaneously
Drug: SHR-2173 Injection/SHR-2173 placebo
Single dose of SHR-2173/placebo given subcutaneously
Drug: SHR-2173 Injection/SHR-2173 placebo
Single dose SHR-2173 injection or matching placebo given subcutaneously
Pharmacokinetics - Cmax
Maximum observed plasma concentration (Cmax)
Time frame: Day 71
Pharmacokinetics - AUC₀-t
Area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC₀-t)
Time frame: Day 71
Pharmacokinetics - AUC₀-inf
Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC₀-inf)
Time frame: Day 71
Pharmacokinetics - Tmax
Time to reach maximum observed plasma concentration (Tmax)
Time frame: Day 71
Pharmacokinetics - t½
Terminal elimination half-life (t½)
Time frame: Day 71
Immunogenicity - Anti-Drug Antibody (ADA)
Incidence and onset time of anti-drug antibody (ADA)
Time frame: Day 71
Safety and Tolerability Based on Incidence and Severity of Treatment Emergent Adverse Events
Number of participants with Adverse events and Serious adverse events
Time frame: Day 71
Plan to share: Undecided
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Atridia Pty Ltd.